2011
Adjuvant chemotherapy in luminal breast cancers
Lim E, Winer EP. Adjuvant chemotherapy in luminal breast cancers. The Breast 2011, 20: s128-s131. PMID: 22015279, DOI: 10.1016/s0960-9776(11)70309-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Agents, HormonalBiomarkersBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm StagingNeoplasms, Hormone-DependentPrognosisRandomized Controlled Trials as TopicReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsAdjuvant endocrine therapyLuminal breast cancerEndocrine therapyBreast cancerEstrogen receptorAdjuvant chemotherapyProgesterone receptorHER2-negative breast cancerER-positive breast tumorsAddition of chemotherapyER-positive diseaseER-positive tumorsUse of chemotherapySubset of patientsSubgroup of patientsER-negative tumorsAdditional therapyCytotoxic chemotherapyEndocrine sensitivityClinicians' estimationTherapeutic responseFavorable outcomeCurrent biomarkersChemotherapyBreast tumors
2009
Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100).
Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I, Ravdin P, Bugarini R, Baehner F, Davidson N, Sledge G, Winer E, Hudis C, Ingle J, Perez E, Pritchard K, Shepherd L, Gralow J, Yoshizawa C, Allred D, Osborne C, Hayes D. Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). Cancer Research 2009, 69: 112-112. DOI: 10.1158/0008-5472.sabcs-09-112.Peer-Reviewed Original ResearchBreast cancer-specific survivalDisease-free survivalER-positive breast cancerAnthracycline-based chemotherapyCancer-specific survivalBreast cancerRecurrence scoreRS categorySuperior breast cancer-specific survivalDFS analysisNew adjuvant treatment strategiesPositive axillary lymph nodesAdjuvant treatment strategiesAxillary lymph nodesHigh-risk patientsUse of chemotherapyLow recurrence scoreHigh recurrence scoreLow RS groupNational Cancer InstituteLack of improvementLog-rank p-valueCensoring deathsLast followChemotherapy benefit
2002
2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology*
Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology*. Journal Of Clinical Oncology 2002, 20: 2895-2903. PMID: 12065567, DOI: 10.1200/jco.2002.04.178.Peer-Reviewed Original Research
2001
New cytotoxic agents and schedules for advanced breast cancer
Burstein H, Bunnell C, Winer E. New cytotoxic agents and schedules for advanced breast cancer. Seminars In Oncology 2001, 28: 344-358. DOI: 10.1053/sonc.2001.26146.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCisplatinClinical Trials as TopicDeoxycytidineDocetaxelDoxorubicinEnzyme InhibitorsFemaleFluorouracilGemcitabineHumansLiposomesPaclitaxelTaxoidsTopoisomerase I InhibitorsTrastuzumabVinblastineVinorelbineConceptsAdvanced breast cancerBreast cancerSide effectsUse of chemotherapyCombination of chemotherapyNovel biological agentsNew cytotoxic agentsTreatment of womenSuch biological therapiesCytotoxic chemotherapyBiological therapyVariety of agentsClinical activityAvailable agentsBetter survivalChemotherapyOral chemotherapeuticsCancerCytotoxic agentsWomenBiological agentsAgentsTherapyImportant studiesNew cytotoxic agents and schedules for advanced breast cancer
Burstein H, Bunnell C, Winer E. New cytotoxic agents and schedules for advanced breast cancer. Seminars In Oncology 2001, 28: 344-358. PMID: 11498829, DOI: 10.1016/s0093-7754(01)90129-0.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCisplatinClinical Trials as TopicDeoxycytidineDocetaxelDoxorubicinEnzyme InhibitorsFemaleFluorouracilGemcitabineHumansLiposomesPaclitaxelTaxoidsTopoisomerase I InhibitorsTrastuzumabVinblastineVinorelbineConceptsAdvanced breast cancerBreast cancerSide effectsUse of chemotherapyCombination of chemotherapyNovel biological agentsNew cytotoxic agentsTreatment of womenSuch biological therapiesCytotoxic chemotherapyBiological therapyVariety of agentsClinical activityAvailable agentsBetter survivalChemotherapyOral chemotherapeuticsCancerCytotoxic agentsWomenBiological agentsAgentsTherapyImportant studies
2000
Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique.
Hellmann K, Hensley M, Schuchter L, Winer E, Meropol N, Pfister D. Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique. Journal Of Clinical Oncology 2000, 18: 2004-6. PMID: 10784645, DOI: 10.1200/jco.2000.18.9.2004.Peer-Reviewed Original Research
1999
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley M, Schuchter L, Lindley C, Meropol N, Cohen G, Broder G, Gradishar W, Green D, Langdon R, Mitchell R, Negrin R, Szatrowski T, Thigpen J, VonHoff D, Wasserman T, Winer E, Pfister D. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. Journal Of Clinical Oncology 1999, 17: 3333-55. PMID: 10506637, DOI: 10.1200/jco.1999.17.10.3333.Peer-Reviewed Original ResearchConceptsUse of dexrazoxaneMetastatic breast cancerClinical practice guidelinesUrothelial toxicityTumor protectionBreast cancerInsufficient evidencePractice guidelinesClinical Oncology Clinical Practice GuidelineLong-term patient qualityOncology Clinical Practice GuidelineStem cell transplantation settingUse of mesnaAnthracycline-containing regimensCardiac risk factorsUse of chemotherapyGrades of RecommendationRadiotherapy-related toxicityMultidisciplinary expert panelLong-term chemotherapyClinical treatment trialsDuration of treatmentLevel of evidenceReduction of nephrotoxicityAmerican Society